CoChat

miR-122 promotes hepatic lipogenesis via inhibiting the LKB1/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease

Open access
Long, Jun-Ke, Dai, Wen, Zheng, Ya-Wen, Zhao, Shui-Ping · 2019 · Molecular Medicine

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is a common hepatic disease with an increasing prevalence but an unclear aetiology. This study aimed to investigate the functional implications of microRNA-122 (miR-122) in the pathogenesis of NAFLD and the possible molecular mechanisms. METHODS: Both in vitro and in vivo models of NAFLD were generated by treating HepG2 and Huh-7 cells with free fatty acids (FFA) and by feeding mice a high-fat diet (HFD), respectively. HE and Oil Red O staining were used to examine liver tissue morphology and lipid deposition, respectively. Immunohistochemical (IHC) staining was used to examine Sirt1 expression in liver tissues. qRT-PCR and Western blotting were employed to measure the expression of miR-122, Sirt1, and proteins involved in lipogenesis and the AMPK pathway. Enzyme-linked immunosorbent assay (ELISA) was used to quantify triglyceride (TG) levels in HepG2 and Huh-7 cells and in liver tissues. The interaction between miR-122 and the Sirt1 gene was further examined by a dual luciferase reporter assay and RNA-immunoprecipitation (RIP). RESULTS: NAFLD hepatic tissues and FFA-treated HepG2 and Huh-7 cells presented excess lipid production and TG secretion, accompanied by miR-122 upregulation, Sirt1 downregulation, and potentiated lipogenesis-related genes. miR-122 suppressed Sirt1 expression via binding to its 3'-untranslated region (UTR). Knockdown of miR-122 effectively mitigated excessive lipid production and suppressed the expression of lipogenic genes in FFA-treated HepG2 and Huh-7 cells via upregulating Sirt1. Furthermore, miR-122 knockdown activated the LKB1/AMPK signalling pathway. CONCLUSION: The inhibition of miR-122 protects hepatocytes from lipid metabolic disorders such as NAFLD and suppresses lipogenesis via elevating Sirt1 and activating the AMPK pathway. These data support miR-122 as a promising biomarker and drug target for NAFLD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s10020-019-0085-2

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Lipid pathology and altered gene expression in NAFLD mice. a HE staining (left) and Oil Red O staining (right) showing lipid accumulation in liver tissues. b Hepatic TG levels were assessed by ELISA. c The relative expression levels of miR-122, Sirt1 and lipogenesis-related genes in control diet- and high-fat diet (HFD)-fed mice were detected by qRT-PCR. d The expression level of Sirt1 was measured by Western blotting. e Quantification of the Western blotting results in d. f, g Representative images (f) and thepositive rate (g) of Sirt1 expression in the liver tissues of NAFLD mice as revealed by IHC staining. All the results are shown as the mean ± SD (n = 3), which are representative of three independent experiments performed in triplicate. *p < 0.05 and **p < 0.01
Fig. 1 Lipid pathology and altered gene expression in NAFLD mice. a HE staining (left) and Oil Red O staining (right) showing lipid accumulation in liver tissues. b Hepatic TG levels were assessed by ELISA. c The relative expression levels of miR-122, Sirt1 and lipogenesis-related genes in control diet- and high-fat diet (HFD)-fed mice were detected by qRT-PCR. d The expression level of Sirt1 was measured by Western blotting. e Quantification of the Western blotting results in d. f, g Representative images (f) and thepositive rate (g) of Sirt1 expression in the liver tissues of NAFLD mice as revealed by IHC staining. All the results are shown as the mean ± SD (n = 3), which are representative of three independent experiments performed in triplicate. *p < 0.05 and **p < 0.01CC BY · PubMed Central
Fig. 2 Effects of FFA on lipogenesis and miR-122 expression in hepatocytes. HepG2 or Huh-7 cells were pre-treated with 1 mM FFA for 24 h. a Oil Red O staining for lipid droplets in HepG2 or Huh-7 cells. b The secretion of TG in HepG2 or Huh-7 cells was measured by ELISA. c, d The relative expression of miR-122 (c) and Sirt1 (d) in HepG2 or Huh-7 cells was determined by qRT-PCR. e The expression level of Sirt1 in HepG2 or Huh-7 cells was measured by Western blotting. f Quantification of the corresponding Western blotting results in e. All the results are shown as the mean ± SD (n = 3), which are representative of three independent experiments performed in triplicate. *p < 0.05 and **p < 0.01
Fig. 2 Effects of FFA on lipogenesis and miR-122 expression in hepatocytes. HepG2 or Huh-7 cells were pre-treated with 1 mM FFA for 24 h. a Oil Red O staining for lipid droplets in HepG2 or Huh-7 cells. b The secretion of TG in HepG2 or Huh-7 cells was measured by ELISA. c, d The relative expression of miR-122 (c) and Sirt1 (d) in HepG2 or Huh-7 cells was determined by qRT-PCR. e The expression level of Sirt1 in HepG2 or Huh-7 cells was measured by Western blotting. f Quantification of the corresponding Western blotting results in e. All the results are shown as the mean ± SD (n = 3), which are representative of three independent experiments performed in triplicate. *p < 0.05 and **p < 0.01CC BY · PubMed Central
Fig. 3 Direct interaction between miR-122 and Sirt1. a The relative expression levels of miR-122 and Sirt1 in HepG2 or Huh-7 cells transfected with miR-122 mimics or inhibitor. b Sequences of the putative binding sites of miR-122 in the 3′-UTR of Sirt1. c An RIP assay was performed to verify the interaction between miR-122 and Sirt1, and the Sirt1 mRNA level was measured by qRT-PCR. d A dual luciferase activity assay was implemented to confirm the direct association between miR-122 and the 3′-UTR of Sirt1. All the results are shown as the mean ± SD (n = 3), which are representative of three independent experiments performed in triplicate. *p < 0.05 and **p < 0.01
Fig. 3 Direct interaction between miR-122 and Sirt1. a The relative expression levels of miR-122 and Sirt1 in HepG2 or Huh-7 cells transfected with miR-122 mimics or inhibitor. b Sequences of the putative binding sites of miR-122 in the 3′-UTR of Sirt1. c An RIP assay was performed to verify the interaction between miR-122 and Sirt1, and the Sirt1 mRNA level was measured by qRT-PCR. d A dual luciferase activity assay was implemented to confirm the direct association between miR-122 and the 3′-UTR of Sirt1. All the results are shown as the mean ± SD (n = 3), which are representative of three independent experiments performed in triplicate. *p < 0.05 and **p < 0.01CC BY · PubMed Central
Fig. 4 Suppression of lipid accumulation by the miR-122 inhibitor via the elevation of Sirt1 expression. a The relative expression level of Sirt1 was assessed by qRT-PCR in HepG2 or Huh-7 cells transfected with shSirt1. b The protein level of Sirt1 was assessed by Western blotting in HepG2 or Huh-7 cells transfected with shSirt1. c Quantification of the corresponding Western blotting results in b. d Oil Red O staining was performed to examine lipid accumulation in HepG2 or Huh-7 cells transfected with miR-122 inhibitor and/or shSirt1. e TG secretion levels in all groups of HepG2 or Huh-7 cells were measured by ELISA. All the results are shown as the mean ± SD (n = 3), which are representative of three independent experiments performed in triplicate. *p < 0.05 and **p < 0.01
Fig. 4 Suppression of lipid accumulation by the miR-122 inhibitor via the elevation of Sirt1 expression. a The relative expression level of Sirt1 was assessed by qRT-PCR in HepG2 or Huh-7 cells transfected with shSirt1. b The protein level of Sirt1 was assessed by Western blotting in HepG2 or Huh-7 cells transfected with shSirt1. c Quantification of the corresponding Western blotting results in b. d Oil Red O staining was performed to examine lipid accumulation in HepG2 or Huh-7 cells transfected with miR-122 inhibitor and/or shSirt1. e TG secretion levels in all groups of HepG2 or Huh-7 cells were measured by ELISA. All the results are shown as the mean ± SD (n = 3), which are representative of three independent experiments performed in triplicate. *p < 0.05 and **p < 0.01CC BY · PubMed Central
Fig. 5 The expression of lipogenesis-associated genes was regulated by miR-122 and Sirt1. HepG2 and Huh-7 cells were pre-transfected with miR-122 inhibitor and/or shSirt1 and were then treated with 1 mM FFA for 24 h. a-e The relative expression levels of SREBP1 (a), FASN (b), SCD1 (c), ACC1 (d) and ApoA5 (e) in HepG2 and Huh-7 cells were detected by qRT-PCR. All the results are shown as the mean ± SD (n = 3), which are representative of three independent experiments performed in triplicate. *p < 0.05 and **p < 0.01
Fig. 5 The expression of lipogenesis-associated genes was regulated by miR-122 and Sirt1. HepG2 and Huh-7 cells were pre-transfected with miR-122 inhibitor and/or shSirt1 and were then treated with 1 mM FFA for 24 h. a-e The relative expression levels of SREBP1 (a), FASN (b), SCD1 (c), ACC1 (d) and ApoA5 (e) in HepG2 and Huh-7 cells were detected by qRT-PCR. All the results are shown as the mean ± SD (n = 3), which are representative of three independent experiments performed in triplicate. *p < 0.05 and **p < 0.01CC BY · PubMed Central
Fig. 6 Downregulation of the LKB1/AMPK signalling pathway by the miR-122-Sirt1 axis. a The expression of Sirt1, LKB1, AMPK and the phosphorylation of AMPK (p-AMPK) were measured by Western blotting in HepG2 or Huh-7 cells that were transfected with miR-122 inhibitor and/or shSirt1. b Quantification of the corresponding Western blotting results in a. All the results are shown as the mean ± SD (n = 3), which are representative of three independent experiments performed in triplicate. *p < 0.05 and **p < 0.01
Fig. 6 Downregulation of the LKB1/AMPK signalling pathway by the miR-122-Sirt1 axis. a The expression of Sirt1, LKB1, AMPK and the phosphorylation of AMPK (p-AMPK) were measured by Western blotting in HepG2 or Huh-7 cells that were transfected with miR-122 inhibitor and/or shSirt1. b Quantification of the corresponding Western blotting results in a. All the results are shown as the mean ± SD (n = 3), which are representative of three independent experiments performed in triplicate. *p < 0.05 and **p < 0.01CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 48 references

Cited by

See all 301

Metadata

Authors
Long, J.-K., Dai, W., Zheng, Y.-W., & Zhao, S.-P.
Affiliations
Second Xiangya Hospital of Central South University (CN)
Corresponding author
Zhao, Shui-Ping
Venue
Molecular Medicine
Published
2019-06-13
Volume
25
Issue
1
Pages
26-26
ISSN
  • 1076-1551 (ISSN-L)
  • 1528-3658
OpenAlex
W2952409891
Cited by
281
References
48
Citations by year
2026: 36 · 2025: 53 · 2024: 52 · 2023: 57 · 2022: 48 · 2021: 21 · 2020: 13 · 2019: 1
FWCI
15.80
Type
journal article
Language
en
Open access
Licence
Locations
  • Molecular Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords
miR-122, non-alcoholic fatty liver disease, hepatic lipogenesis, SIRT1, LKB1/AMPK pathway, microRNA, free fatty acids, triglyceride secretion, 3' untranslated region, lipid metabolism, hepatocytes, high-fat diet, biomarkers, therapeutic target
MeSH terms
Enzyme-Linked Immunosorbent Assay, Humans, Immunohistochemistry, Liver, Signal Transduction, MicroRNAs, Cell Line, Tumor, Lipogenesis, Lipid Metabolism, AMP-Activated Protein Kinases, Sirtuin 1, Hep G2 Cells, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: miR-122 promotes hepatic lipogenesis via inhibiting the LKB1/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease. https://app.cochat.ai/papers/10.1186/s10020-019-0085-2
The paper
Long, J.-K., Dai, W., Zheng, Y.-W., & Zhao, S.-P. (2019). miR-122 promotes hepatic lipogenesis via inhibiting the LKB1/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease. Molecular Medicine. https://doi.org/10.1186/s10020-019-0085-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.